# Wegovy 7.2 mg: What the Higher Dose Actually Costs

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-11-02

Canonical page: https://glpwatchdog.org/research/wegovy-7-2-mg-what-it-costs

> At 7.2 mg, abnormal skin sensation was reported by 22%, against 6% at 2.4 mg and zero on placebo. Nausea barely moves. The cost of escalating is not where anyone expects it.

## Key points

- Dysesthesia (burning, tingling, skin pain): 0% placebo, 6% at 2.4 mg, 22% at 7.2 mg.
- Nausea moves only 35% to 39%; constipation 19% to 20%. Hair loss doubles, 3% to 6%.
- The label allows 7.2 mg only after tolerating 2.4 mg for four weeks, where more loss is indicated.
- Table 4 lists only what is WORSE at the higher dose. It is not a general safety profile.

There is a higher dose of Wegovy now, and its label carries a number almost nobody is discussing. **Dysesthesia** (abnormal skin sensation, which the label defines as covering burning, tingling, heightened sensitivity and skin pain) was reported by **22%** of people on 7.2 mg, more than one person in five. At 2.4 mg it was 6%. On placebo it was **zero**.[1] If you are weighing this dose against nausea, you are weighing the wrong side effect.

## What the table shows

The label reports the 7.2 mg dose against both 2.4 mg and placebo in the same table. That is unusually useful, because it shows what escalating costs, separately from what the drug costs in general.[1]

*Wegovy 7.2 mg (N=1,311) against 2.4 mg (N=304) and placebo (N=303). Section 6.1, Table 4.*

| Effect | Placebo | 2.4 mg | 7.2 mg |
| --- | --- | --- | --- |
| **Dysesthesia** | 0% | 6% | **22%** |
| Nausea | 13% | 35% | 39% |
| Vomiting | 6% | 16% | 22% |
| Constipation | 8% | 19% | 20% |
| Hair loss | 1% | 3% | 6% |
| Fatigue | 5% | 9% | 11% |
| Dizziness | 1% | 5% | 6% |

Compare the last two columns. Nausea moves four points and constipation one, while dysesthesia moves **sixteen** and hair loss doubles. The gastrointestinal effects everyone braces for are largely already priced in by 2.4 mg; what the higher dose adds is mostly something else.

> Going from 2.4 to 7.2 mg barely changes the nausea. It nearly quadruples the skin symptoms.

## What dysesthesia actually means

It is not a familiar word and the label spells out what it is counting: allodynia, burning sensation, dysesthesia itself, hyperesthesia, hyperpathia, pain of skin, and paresthesia.[1] In ordinary language, that is skin that burns, tingles, prickles, feels raw, or hurts at a touch that should not hurt. How it compares across Ozempic, Zepbound and Mounjaro is in [GLP-1 skin sensitivity, rash and itching](https://glpwatchdog.org/research/glp1-skin-sensitivity-rash-and-itching).

This is a sensory nerve symptom, not a gut one, and it sits in a different category from everything else on the list. The label does not say why it happens. It does say what happened next: of 288 people on 7.2 mg who had it, 23% had the dose reduced, 8% paused and 2% stopped; most of those recovered, faster than people who changed nothing, and 18% overall had no recovery reported by the time the trial ended. When 38 people who had recovered went back up to 7.2 mg, it returned in 17.[1]

> **New or worsening numbness, burning or tingling deserves a conversation rather than tolerance.** Nerve symptoms are one of the few side-effect categories where waiting it out is not automatically reasonable, and where the underlying cause matters: diabetes, B12 status and other medicines all produce the same picture. Do not assume it is the dose just because the dose went up.

## How you get to this dose at all

The label does not treat 7.2 mg as the destination. It is reached only after **at least four weeks** of tolerating 2.4 mg, and only where further weight reduction is clinically indicated, and the label asks prescribers to weigh how well the drug is working and how well it is tolerated when picking the dose.[1]

That is narrower than the way higher doses usually get discussed. The label does not present 7.2 mg as a reward for doing well or as the natural end of the ladder. Our [titration planner](https://glpwatchdog.org/tools/glp1-titration-planner) prints the schedule from the label itself.

## What the extra dose buys

The FDA approved 7.2 mg, sold as Wegovy HD, in March 2026.[3] The trial behind it, STEP UP, ran 72 weeks. On 7.2 mg, weight fell 18.7%, against 15.6% on 2.4 mg and 3.9% on placebo.[2] The step up bought about **three percentage points**. The same paper puts dysesthesia at 22.9% on 7.2 mg, 6.0% on 2.4 mg and 0.5% (one person) on placebo, the same pattern the label shows.[2]

It also costs more in money. Novo’s own self-pay pharmacy lists the 7.2 mg pen at a higher monthly price than every 2.4 mg-and-below dose.[4] We keep the dated figures on the [price tracker](https://glpwatchdog.org/price-tracker). Three points of weight, against a one-in-five chance of skin symptoms and a higher bill, is the trade the label leaves you to weigh with a prescriber.

If you buy brand semaglutide through a telehealth seller instead, check which product it lists, because Ozempic is a different label from Wegovy. [SkinnyRx](https://glpwatchdog.org/reviews/skinnyrx), [Wellorithm](https://glpwatchdog.org/reviews/wellorithm) and [Concierge MD LA](https://glpwatchdog.org/reviews/concierge-md-la) list both Wegovy and Ozempic pens; Wellorithm ties its brand price to a three-month plan paid up front. [TrimRx](https://glpwatchdog.org/reviews/trimrx), [Gala](https://glpwatchdog.org/reviews/gala) and [Push Health](https://glpwatchdog.org/reviews/push-health) list brand Ozempic. None of the listings we recorded names the 7.2 mg strength, so ask before you assume a seller can fill it.

Some sellers split the bill instead of reselling the pen. [AgelessRx](https://glpwatchdog.org/reviews/agelessrx) has NovoCare bill you for Wegovy directly and charges its own monthly monitoring fee on top, so the cost of the pen and the cost of the care arrive as two separate charges.

Insurance is the other route to the pen, though some plans, [Cigna among them](https://glpwatchdog.org/research/does-cigna-cover-zepbound-and-wegovy), treat 7.2 mg as a step after a stretch on 2.4 mg. [FitRx](https://glpwatchdog.org/reviews/fitrx) and [AM Rx](https://glpwatchdog.org/reviews/amrx) both sell a membership whose coordinators pursue insurance approval for Wegovy and Ozempic, among other brands. FitRx says that membership does not include the medication, and AM Rx still requires its membership when insurance covers the drug.

## One thing this table is not

Before quoting anything from Table 4, know its inclusion rule. It lists reactions occurring in at least 2% of people *and* more often than on both 2.4 mg and placebo.[1]

It is built specifically to show what gets *worse* at the higher dose. Anything equally common at both doses is not in it. So this is a table about the marginal cost of escalating, not a safety profile of the drug, and reading it as one would leave out every reaction that is just as common at 2.4 mg.

For what the doses buy on the other side of that trade, our [semaglutide timeline](https://glpwatchdog.org/research/semaglutide-results-timeline) sets out what the trials recorded, and [how long side effects last](https://glpwatchdog.org/research/how-long-do-glp1-side-effects-last) covers the escalation-week pattern.

## Frequently asked questions

### What is the highest dose of Wegovy?

7.2 mg once weekly. The label allows it only after at least four weeks on 2.4 mg that the patient has tolerated, and only where additional weight reduction is clinically indicated, weighing both response and tolerability.

### What is the main side effect at 7.2 mg?

Dysesthesia (abnormal skin sensation), at 22% against 6% at 2.4 mg and 0% on placebo. The label defines it as including allodynia, burning, heightened sensitivity, skin pain and tingling. It is by far the largest increase in the table.

### Does the nausea get much worse at the higher dose?

Barely. Nausea goes from 35% at 2.4 mg to 39% at 7.2 mg, and constipation from 19% to 20%. The gastrointestinal effects are largely already priced in at the lower dose; what escalation mainly adds is the skin sensation, and a doubling of hair loss from 3% to 6%.

### Does the skin symptom go away?

Often, but not always. Of 288 people on 7.2 mg who had it, 18% had no recovery reported by the end of the trial, and most of them had kept the same dose. Most who paused, cut the dose or stopped did recover, and faster than those who changed nothing. Of 38 who recovered and went back up to 7.2 mg, 17 (45%) had it again, according to the label.

### Is 7.2 mg the goal everyone works toward?

No. The label frames it as an option where further weight reduction is clinically indicated and tolerability allows, not as the end of the ladder or a reward for tolerating 2.4 mg.

## References

1. Novo Nordisk Inc. WEGOVY (semaglutide) — US Prescribing Information, Section 6.1 Table 4 (adverse reactions at 7.2 mg, N=1,311) and Section 2.1 dosage escalation (revised 06/2026). DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
2. Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology. 2025. PMID: 40961952. https://pubmed.ncbi.nlm.nih.gov/40961952/
3. Novo Nordisk FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile. PR Newswire, March 19, 2026. 2026. https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-new-wegovy-hd-injection-delivering-the-highest-weight-loss-to-date-for-a-wegovy-injection-adding-to-its-already-expansive-clinical-profile-302718982.html
4. Novo Nordisk Wegovy savings offer and NovoCare Pharmacy self-pay pricing. NovoCare, accessed October 17, 2026. 2026. https://www.novocare.com/obesity/products/wegovy/savings-offer.html

---

Cite as: GLP Watchdog, Nora Bissett, "Wegovy 7.2 mg: What the Higher Dose Actually Costs", published 2026-08-19, updated 2026-11-02. https://glpwatchdog.org/research/wegovy-7-2-mg-what-it-costs

Canonical HTML page: https://glpwatchdog.org/research/wegovy-7-2-mg-what-it-costs

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
